08:20 AM EDT, 10/10/2024 (MT Newswires) -- Theratechnologies ( THTX ) rose 12% to US$1.36 in premarket trade after reporting a swing to third-quarter profit on higher revenue.

The company reported a profit of US$3.1 million, compared with a loss of US$0.75 million, last year.

Revenue climbed 8.4% to US$22.6 million, boosted by a 27% increase in Egrifta net sales to US$16.7 million. Trogarzo sales fell 23% to US$5.9 million.

Last month, Theratechnologies ( THTX ) said its contract manufacturer for Egrifta shut down its facility following an FDA inspection. The company has implemented measures to manage the inventory levels of Egrifta to meet patient demand until mid-January. These measures will result in a revenue shortfall for Egrifta in fiscal year 2024.

The company has therefore trimmed its 2024 revenue guidance to between US$83 and US$85 million from US$87 to US$90 million, to account for the potential supply constraint of Egrifta in late November and the year-to-date trend of Trogarzo sales.

Theratechnologies ( THTX ) expects to make up for sales not recorded in the fourth quarter in the first half of 2025.

Shares were last seen up US$0.14, to US$1.36 in U.S. premarket trade.